IRIS Accounts Production v25.1.4.42 13186136 Board of Directors 29.2.24 28.2.25 28.2.25 false true false false false true false Ordinary A 1.00000 Ordinary B 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh131861362024-02-28131861362025-02-28131861362024-02-292025-02-28131861362023-02-28131861362023-03-012024-02-28131861362024-02-2813186136ns15:EnglandWales2024-02-292025-02-2813186136ns14:PoundSterling2024-02-292025-02-2813186136ns10:Director12024-02-292025-02-2813186136ns10:PrivateLimitedCompanyLtd2024-02-292025-02-2813186136ns10:SmallEntities2024-02-292025-02-2813186136ns10:AuditExempt-NoAccountantsReport2024-02-292025-02-2813186136ns10:SmallCompaniesRegimeForAccounts2024-02-292025-02-2813186136ns10:FullAccounts2024-02-292025-02-281318613612024-02-292025-02-2813186136ns10:OrdinaryShareClass12024-02-292025-02-2813186136ns10:OrdinaryShareClass22024-02-292025-02-2813186136ns10:Director22024-02-292025-02-2813186136ns10:RegisteredOffice2024-02-292025-02-2813186136ns5:CurrentFinancialInstruments2025-02-2813186136ns5:CurrentFinancialInstruments2024-02-2813186136ns5:ShareCapital2025-02-2813186136ns5:ShareCapital2024-02-2813186136ns5:RetainedEarningsAccumulatedLosses2025-02-2813186136ns5:RetainedEarningsAccumulatedLosses2024-02-2813186136ns5:NetGoodwill2024-02-292025-02-2813186136ns5:IntangibleAssetsOtherThanGoodwill2024-02-292025-02-2813186136ns5:NetGoodwill2024-02-2813186136ns5:NetGoodwill2025-02-2813186136ns5:NetGoodwill2024-02-2813186136ns5:FurnitureFittings2024-02-2813186136ns5:MotorVehicles2024-02-2813186136ns5:ComputerEquipment2024-02-2813186136ns5:FurnitureFittings2024-02-292025-02-2813186136ns5:MotorVehicles2024-02-292025-02-2813186136ns5:ComputerEquipment2024-02-292025-02-2813186136ns5:FurnitureFittings2025-02-2813186136ns5:MotorVehicles2025-02-2813186136ns5:ComputerEquipment2025-02-2813186136ns5:FurnitureFittings2024-02-2813186136ns5:MotorVehicles2024-02-2813186136ns5:ComputerEquipment2024-02-2813186136ns5:WithinOneYearns5:CurrentFinancialInstruments2025-02-2813186136ns5:WithinOneYearns5:CurrentFinancialInstruments2024-02-2813186136ns5:Secured2025-02-2813186136ns5:Secured2024-02-2813186136ns10:OrdinaryShareClass12025-02-2813186136ns10:OrdinaryShareClass22025-02-28
REGISTERED NUMBER: 13186136 (England and Wales)









KHB PHARMA LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 28 FEBRUARY 2025






KHB PHARMA LTD (REGISTERED NUMBER: 13186136)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


KHB PHARMA LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 28 FEBRUARY 2025







DIRECTORS: K Bhudia
C K Chan





REGISTERED OFFICE: Churchgate House
3 Church Road
Whitchurch
Cardiff
SOUTH GLAMORGAN
CF14 2DX





REGISTERED NUMBER: 13186136 (England and Wales)






KHB PHARMA LTD (REGISTERED NUMBER: 13186136)

BALANCE SHEET
28 FEBRUARY 2025

28.2.25 28.2.24
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 201,332 234,887
Tangible assets 5 25,121 30,957
226,453 265,844

CURRENT ASSETS
Stocks 6 25,500 26,000
Debtors 7 82,540 123,802
Cash at bank and in hand 240,126 95,684
348,166 245,486
CREDITORS
Amounts falling due within one year 8 546,344 488,558
NET CURRENT LIABILITIES (198,178 ) (243,072 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

28,275

22,772

CAPITAL AND RESERVES
Called up share capital 11 100 100
Retained earnings 28,175 22,672
SHAREHOLDERS' FUNDS 28,275 22,772

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 28 February 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 28 February 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

KHB PHARMA LTD (REGISTERED NUMBER: 13186136)

BALANCE SHEET - continued
28 FEBRUARY 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12 June 2025 and were signed on its behalf by:





K Bhudia - Director


KHB PHARMA LTD (REGISTERED NUMBER: 13186136)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

1. STATUTORY INFORMATION

KHB Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern
The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. In making their assessment, the directors have reviewed the balance sheet, the likely future cashflows of the business and have considered the facilities that are available to the company along with their continued support.

At the date of approving the financial statements the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and that the going concern basis of accounting remains appropriate. The directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Significant judgements and estimates
In the application of the company's accounting policies, which are described in note 2, management are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on a ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Useful economic lives of intangible assets
The annual amortisation charge of intangible fixed assets is a fixed rate based on the useful economic life of the asset. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect the current estimate. See notes for the carrying amount of the intangible fixed assets and accounting policies in note 2 for the useful economic lives of each class of asset.

KHB PHARMA LTD (REGISTERED NUMBER: 13186136)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

2. ACCOUNTING POLICIES - continued

Turnover
Turnover is measured at fair value of the consideration received or receivable net of VAT and discounts. The policies adopted for the recognition of turnover are as follows:-

- Revenue represents retail sales to customers and is measured at fair value of the consideration received or receivable and is recognised when all risk and rewards of ownership are transferred to the end customer.
- NHS income is recognised in the period which it is due.
- Services provided to the customer during the normal course of business. Turnover is recognised at the point when all benefits of the services provided are transferred to the customer.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2021, is being amortised evenly over its estimated useful life of ten years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Tangible fixed assets held for the company's own use are stated at cost less accumulated depreciation and accumulated impairment losses.

Depreciation is provided at the following annual rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives:

Fixtures and equipment - 20% reducing balance
Motor vehicles - 25% reducing balance
Computer equipment - 33% cost

At each balance sheet date, the company reviews the carrying amount of its tangible assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of the asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Stocks
Stocks are valued at the lower of cost and estimated selling price less cost to sell after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


KHB PHARMA LTD (REGISTERED NUMBER: 13186136)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Operating lease commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Provisions
Provisions are recognised when the company has an obligation at the balance sheet date as a result of a past event, it is probable that an outflow of economic benefit will be required in settlement and the amount can be reliable estimated.

Impairment
Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the assets cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit and loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

KHB PHARMA LTD (REGISTERED NUMBER: 13186136)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

2. ACCOUNTING POLICIES - continued

Cash and cash equivalents
Cash and cash equivalents are basic financial instruments and include cash in hand and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments'. Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include trade and other debtors, loans to related companies and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

Basic financial liabilities
Basic financial liabilities, including trade and other creditors, loans to related companies and bank loans are initially recognised at transaction price unless the arrangement constitutes a financial transaction, where the the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 7 (2024 - 7 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 29 February 2024
and 28 February 2025 335,553
AMORTISATION
At 29 February 2024 100,666
Amortisation for year 33,555
At 28 February 2025 134,221
NET BOOK VALUE
At 28 February 2025 201,332
At 28 February 2024 234,887

KHB PHARMA LTD (REGISTERED NUMBER: 13186136)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

5. TANGIBLE FIXED ASSETS
Fixtures Motor Computer
& equipment vehicles equipment Totals
£    £    £    £   
COST
At 29 February 2024 52,295 5,500 2,136 59,931
Additions - - 374 374
At 28 February 2025 52,295 5,500 2,510 60,305
DEPRECIATION
At 29 February 2024 25,134 2,868 972 28,974
Charge for year 5,352 647 211 6,210
At 28 February 2025 30,486 3,515 1,183 35,184
NET BOOK VALUE
At 28 February 2025 21,809 1,985 1,327 25,121
At 28 February 2024 27,161 2,632 1,164 30,957

6. STOCKS
28.2.25 28.2.24
£    £   
Stocks 25,500 26,000

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
28.2.25 28.2.24
£    £   
Trade debtors 72,295 112,655
Other debtors 10,245 11,147
82,540 123,802

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
28.2.25 28.2.24
£    £   
Bank loans and overdrafts 5,364 -
Trade creditors 88,260 78,726
Taxation and social security 57,847 24,935
Other creditors 394,873 384,897
546,344 488,558

9. LEASING AGREEMENTS
At 28 February 2025, the company had total commitments under non-cancellable operating leases over the remaining life of those leases of £96,281 - (2024 - £109,827).

KHB PHARMA LTD (REGISTERED NUMBER: 13186136)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

10. SECURED DEBTS

The following secured debts are included within creditors:

28.2.25 28.2.24
£    £   
Pentyrch Pharmacy Limited 154,000 154,000
K Bhudia 201,362 212,634
355,362 366,634

Pentyrch Pharmacy Limited and K Bhudia hold fixed and floating charges, containing negative pledge.

The floating charge is over all existing and future property and undertakings owned by the company.

The fixed charge is over all book debts, present and future goodwill, all company contracts (including NHS) and existing and future tangible fixed assets.

11. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 28.2.25 28.2.24
value: £    £   
60 Ordinary A £1 60 60
40 Ordinary B £1 40 40
100 100

12. TRANSACTIONS WITH DIRECTORS

As at 28 February 2025 the company owed Mr K Bhudia £215,275 (2024 - £212,634) which is included within the creditors amounts falling due within one year. The balance is interest free and repayable on demand.

13. RELATED PARTY DISCLOSURES

As at 28 February 2025 an amount of £154,000 (2024 - £154,000) was owed to Pentyrch Pharmacy Limited. Pentyrch Pharmacy Limited is a company which one of the directors has a vested interest in. The amount is included within creditors falling due within one year. The balance is interest free and repayable on demand.

Included in the profit and loss of the company is an amount of £475 (2024 - £nil) from Pentyrch Pharmacy Limited in respect of purchases. As at 28 February 2025 an amount of £475 (2024 - £nil) was owed to Pentyrch Pharmacy Limited.

As at 28 February 2025 an amount of £24,500 (2024 - £10,379) was owed to H Field. H Field is a shareholder of the company. The amount is included within creditors falling due within one year. The balance is interest free and repayable on demand.